Skip to content
DataLookout
Menu

NCT06996119

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 1 year 5 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from May 25, 2027 to Nov 5, 2028
    • Eligibility criteria expanded, about 42 words
    • Secondary endpoints: details revised at 8 of 12 entries
    • Study description revised
  2. Minor Start date changed from estimate of May 25, 2026 to Jun 12, 2026v3
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of grade 3 or higher adverse events (AEs)
Timeframe: From starting the first emapalumab dose to the first observation of a primary safety endpoint (PSE) event or day 28 post-hematopoietic cell transplantation (HCT), whichever comes first
Incidence of severe infusion reaction
Timeframe: From starting the first emapalumab dose to the first observation of a PSE event or day 28 post-HCT, whichever comes first
Incidence of primary graft failure
Timeframe: From starting the first emapalumab dose to the first observation of a PSE event or day 28 post-HCT, whichever comes first
Non-relapse mortality (NRM)
Timeframe: From starting the first emapalumab dose to the first observation of a PSE event or day 28 post-HCT, whichever comes first

Secondary (12)

Incidence of grade 2-4 acute graft-versus-host-disease (aGVHD)
Incidence of grade 3 or higher AEs
Overall survival
Progression free survival
GVHD relapse-free survival (GRFS)
Show 7 moreShow less
Relapse/progression
NRM
Incidence of aGVHD
Incidence of chronic GVHD
Incidence of infection
Absolute neutrophil count recovery
Platelet recovery

Arms and interventions

Prevention (emapalumab, cyclophosphamide)Experimental

Patients receive fludarabine IV on days -7 to -3 and melphalan IV over 1 hour on day -2 or busulfan IV on days -7 and -6 and fludarabine IV on days -7 to -2. Patients receive HCT infusion on day 0 per institutional standards of practice. Patients also receive emapalumab IV over 1 hour on days -8. -1, -7, 14 and 21, cyclophosphamide IV on days 3 and 4, tacrolimus IV or PO on days 5-95, mycophenolate mofetil IV or PO on days 5-35. Additionally, patients undergo chest CT and ECHO or MUGA at baseline and blood sample collection throughout the study.

Procedures: Biospecimen Collection, Computed Tomography, Echocardiography Test, Hematopoietic Cell Transplantation, Multigated Acquisition Scan

Drugs: Busulfan, Cyclophosphamide, Fludarabine, Melphalan, Mycophenolate Mofetil, Tacrolimus

Biologicals: Emapalumab

Other: Questionnaire Administration

Sites

1 site in 1 country

  • City of Hope Medical CenterDuarte, California, United States